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Abstract
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Background—Percutaneous lymphatic intervention (PCL) is a promising new therapy for plastic
bronchitis (PB). We characterized bronchoalveolar lavage (BAL) and cast morphology in
surgically repaired congenital heart disease (CHD) patients with PB during PCL. We quantified
respiratory and bronchoscopic characteristics and correlated them with post-intervention
respiratory outcomes.
Methods—We retrospectively reviewed patients with PB and surgically repaired CHD
undergoing PCL and bronchoscopy at our institution. Pre-intervention characteristics,
bronchoscopy notes, BAL cell counts, virology, and cultures were collected. A pathologist blinded
to clinical data reviewed cast specimens. Respiratory outcomes were evaluated through
standardized telephone questionnaire.
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Results—Sixty-two patients were included with a median follow-up of 20 months. No patients
experienced airway bleeding, obstruction, or prolonged intubation related to bronchoscopy. Of
BAL infectious studies, the positive results were 4 (8%) fungal, 6 (11%) bacterial, and 6 (14%)
viral. Median BAL count per 100 cells for neutrophils, lymphocytes, and eosinophils were 13, 10,
and 0, respectively. Of 23 bronchial casts analyzed, all contained lymphocytes, and 19 (83%) were
proteinaceous, with 14 containing neutrophils and/or eosinophils. Median BAL neutrophil count
was greater in patients with proteinaceous neutrophilic or eosinophilic casts compared to casts
without neutrophils or lymphocytes (p=0.030). Post-intervention, there was a significant reduction
in respiratory medications and support and casting frequency.
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Conclusions—The predominance of neutrophilic proteinaceous casts and high percentage of
positive BAL infectious studies support short-term fibrinolytic and anti-infective therapies in PB in
select patients. Flexible bronchoscopy enables safe assessment of cast burden. PCL effectively
treats PB and reduces respiratory therapies.
Keywords
percutaneous lymphatic intervention; bronchoalveolar lavage; bronchial casts; cast frequency; cast
pathology; surgically repaired congenital heart disease; Fontan physiology; thoracic duct
embolization

Introduction
Author Manuscript

Plastic bronchitis (PB) is an uncommon, but potentially life-threatening complication that
can occur in patients after surgical repair of congenital heart disease. The estimated
prevalence of PB after Fontan palliation is 4% and 5-year mortality is estimated up to
50%1,2. While PB has also been reported in patients with sickle cell disease, chronic lung
diseases, and primary lymphatic abnormalities, it is most widely described in patients with
surgically repaired congenital heart disease (CHD)3–5. PB is characterized by production of
bronchial casts in the airway. Casts are composed of cellular and proteinaceous material that
solidifies in the tracheobronchial tree. While smaller casts can be expectorated
spontaneously, larger casts often pose significant risk for airway obstruction and require
bronchoscopic removal.
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Although the etiology of PB is not fully understood, recent advances in lymphatic imaging
techniques have provided insight into underlying abnormalities in lymphatic flow associated
with PB, including pulmonary lymphatic perfusion syndrome (PLPS)6. These lymphatic
abnormalities, combined with elevated central venous pressure and low cardiac output, are
thought to cause inflammation and injury to the alveoli and surrounding capillaries2,7–9.
Loss of alveolar-capillary membrane integrity facilitates exudation of material into the
airways leading to cast formation.
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The initial cast morphology classification system for cast morphology distinguished cellular
inflammatory casts from acellular casts made of mucin and fibrin4. Originally, patients with
CHD were thought to have mucin-predominant acellular casts secondary to mucin
hypersecretion in the airways. More recent cast analysis in CHD patients revealed both a
high fibrin predominance and lymphocyte-predominant cellularity3,10. The current proposed
classification system distinguishes casts on the basis of their underlying etiology, namely
structural CHD, primary lymphatic disorders, and non-lymphatic disorders3. Further
description of cast morphology is important to understand disease pathogenesis and may
have therapeutic implications.
Current medical management of PB focuses on optimizing hemodynamic pressures and
improving respiratory clearance. Medication regimens including pulmonary vasodilators,
inhaled steroids, mucolytics, bronchodilators, and antibiotics have been reported in the
literature with limited efficacy11–13. Short-term administration of fibrinolytics, such as
aerosolized tissue plasminogen activator (tPA), have been shown to improve symptoms and
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decrease PB cast size10. Catheter-based interventions, such as Fontan fenestration creation
or enlargement, and surgical heart transplantation have demonstrated utility14,15. Dietary fat
restriction and thoracic duct ligation have also shown some efficacy16,17. While
combinations of these therapies have shown promise, some patients with PB continue to
develop casts, leading investigators to identify a more reliably effective treatment.
Percutaneous lymphatic intervention (PCL) with thoracic duct embolization is the preferred
approach for treating patients with PB at our institution6,18. Flexible bronchoscopy is
performed immediately prior to intervention to assess for cast burden and airway injury.

Author Manuscript

In this study, we aimed to characterize bronchoalveolar lavage (BAL) and bronchial cast
morphology in patients with surgically repaired CHD complicated by PB at time of PCL.
We hypothesized that there would be an association between neutrophilic cast histology and
neutrophilia on BAL. We also aimed to focus on the technique and safety assessing for cast
burden with flexible bronchoscopy. We sought to assess intermediate-term respiratory
outcomes after intervention by assessing post-intervention casting frequency, respiratory
support, and medications.

Materials and Methods
Patient Selection

Author Manuscript

We retrospectively reviewed pediatric patients with surgically repaired CHD and PB that
underwent PCL and bronchoscopy at our institution from August 2013 to October 2017.
Patients were excluded if bronchoscopy was not performed at the time of intervention.
While a few patients had repeat lymphatic interventions at our institution, we analyzed the
initial intervention as the index procedure for inclusion in this cohort. Approval was
obtained from the Institutional Review Board prior to study initiation.
Lymphatic Imaging and Intervention
The central lymphatic system was initially imaged with dynamic contrast-enhanced
magnetic resonance lymphangiogram (DCMRL) and T2-weighted MRI as previously
described by Dori et al18–20. Hemodynamic cardiac catheterization was performed prior to
the lymphatic intervention in each case. Intranodal lymphangiography was used to visualize
the lymphatic vessels, as described by Nadolski and Itkin21. Thoracic duct access was then
obtained through a percutaneous transabdominal approach. Complete embolization of the
thoracic duct or selective embolization of lymphatic branches was performed using the
techniques reported by Dori et al6,18.
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Data Collection
Electronic medical records were reviewed to obtain the demographics, past medical and
surgical history, bronchoscopy procedure notes, and specific details regarding the lymphatic
intervention. Casting frequency was defined based on the initial admission note according to
the following categories: never, every few months, monthly, every few weeks, weekly, every
few days, and daily. The need for respiratory support pre-intervention was categorized as
both a dichotomous yes/no variable for any respiratory support and as none, nasal cannula,
intermittent continuous positive airway pressure or bi-level positive airway pressure (CPAP
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or BLPAP), continuous CPAP or BLPAP, or intubated with mechanical ventilation. Fontan
pressures were obtained from cardiac catheterizations performed immediately prior to the
intervention.
Bronchoscopy and Bronchoalveolar Lavage
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Flexible bronchoscopy was performed prior to PCL to visualize the mucosal integrity of the
tracheobronchial tree and assess the cast burden. Flexible bronchoscopy was performed
either through an endotracheal tube or with the use of a laryngeal mask. Identified casts were
removed via flexible bronchoscopy. An Olympus Flexible bronchoscopy with a 2.0 mm
working channel was used for all procedures. Cast removal was performed with the use of a
2.0 forceps via the working channel of the bronchoscope or with the use of gentle suction.
All casts removed were sent for microscopic analysis. BAL was performed by wedging the
flexible bronchoscope in a subsegmental bronchus, instilling 2 aliquots of normal saline, and
collecting the lavage sample in a sterile tube. The bronchial segment chosen for lavage was
the area with the most visible secretions or, if there were none, the right middle lobe or
lingula.
BAL samples were sent for cell count, cytologic analysis, viral PCR, bacterial, fungal, and
acid-fast bacilli cultures. BAL bacterial cultures were considered positive if the organism
identified grew in >10,000 CFU/mL. Fungal pathogen and acid-fast bacilli cultures were
positive if a pathogen grew on appropriate media. BAL virology testing for respiratory
pathogens was performed using a viral PCR panel that tested for adenovirus, human
metapneumovirus, influenza, parainfluenza, respiratory syncytial virus, and rhinovirus.
Cast Analysis
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Casts were included for analysis if they were collected within one month of intervention.
Hematoxylin and eosin stained sections of surgical pathology or cell block specimens were
examined by a single pathologist blinded to clinical data for extracellular matrix component
(proteinaceous or mucinous) and for cellular component. Each component was evaluated
separately within both the denser proteinaceous material and in the adjacent mucinous
material. The purpose of this analysis was not to create a new classification scheme but
rather to be precise regarding the cells identified and extra-cellular components of the casts
observed and to determine whether those features correlated with clinical features.
Intermediate term Follow-up
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Families were contacted via telephone to inquire about post-intervention outcomes. All
phones calls were conducted between January 2018 and April 2018 using a standardized
questionnaire to uniformly collect data on casting frequency, cast appearance, respiratory
support and medications, and post-intervention surgical procedures.
Statistical Methods
Standard descriptive statistics were used to summarize demographic, historical,
bronchoscopic, intervention, and morphology variables. Continuous variables were
expressed as a median with interquartile range (IQR), and categorical variables were
reported as a count with percentage of total. Wilcoxon rank-sum tests were conducted to
Pediatr Pulmonol. Author manuscript; available in PMC 2019 November 01.
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compare BAL neutrophil counts and baseline casting frequency associated with positive and
negative cultures, as well as with proteinaceous casts with neutrophils and/or eosinophils
and proteinaceous casts without neutrophils or eosinophils. Patients who failed lymphatic
intervention and subsequently underwent heart transplantation were excluded from the postintervention analyses of respiratory support, medications, and casting frequency, given that
cessation of respiratory medications and casting would be attributed to transplant success
and not lymphatic intervention. Comparison of pre- and post-intervention respiratory
medications for each patient was conducted using a McNemar’s test. A Wilcoxon signedrank test was used to compare the casting frequency pre- and post-intervention. Two-tailed
p-values were considered statistically significant if <0.05.

Results
Author Manuscript

We identified 62 patients with plastic bronchitis and surgically repaired CHD who
underwent PCL at our institution from August 2013 to October 2017. Baseline
characteristics for the cohort are summarized in Table 1. The majority (87%) of patients had
Fontan physiology at time of intervention, defined as single ventricle physiology with total
(superior and inferior) cavopulmonary connection. Two patients had only completed
superior cavopulmonary connection, resulting in Glenn physiology. The six patients with 2ventricle physiology included one patient with congenital heart disease status-post
orthotopic heart transplantation prior to the intervention. Three patients in the cohort initially
had lymphatic procedures attempted that were halted due to inability to access the thoracic
duct. All 3 patients had subsequent lymphatic interventions successfully completed on their
second attempt, which we considered the index procedure for inclusion.
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The median times from most recent cardiac surgery before PB diagnosis to the onset of PB
and from PB onset to PCL were 20 months (IQR 4 to 47 months) and 9 months (IQR 4 to 34
months), respectively. The majority (90%) of patients had evidence of casting within 1
month prior to the intervention. Pre-intervention casting frequency was variable, with 31%
of patients casting daily, 26% casting weekly, 21% casting every few weeks, and 11%
casting monthly (Table 1).
Bronchoscopy Results
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Flexible bronchoscopy was performed by a group of experienced bronchoscopists, each of
whom perform greater than 20 bronchoscopies annually and are on the bronchoscopy team
at our institution. Review of the bronchoscopy procedure notes indicated that none of the
patients experienced bleeding of the airways or obstruction leading to hypoxemia during
bronchoscopy. Fifty-nine (95%) patients were extubated immediately after intervention with
concurrent bronchoscopy. For the three patients who required intubation post-intervention,
their continued requirements for ventilatory support were attributed to underlying lung
disease and were not considered a complication of bronchoscopy or intervention.
Of the 62 patients, BAL samples were obtained in 54 patients during bronchoscopy and
analyzed for cell count and infectious analysis. The predominant cell types identified were
macrophages, neutrophils, and lymphocytes with median values of 45, 13, and 10
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respectively (Figure 1). Eosinophils and monocytes represented a smaller proportion of the
cell types with median values of 0 and 1, respectively (Figure 1).
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All 54 BAL samples had fluid sent for bacterial culture. Bacterial species were identified in
6 (11%) of the 54 BALs and included Moraxella catarrhalis, Pseudomonas aeruginosa, Staph
aureus, and Haemophilus influenzae (Table 2). Fifty of the BAL samples were sent for
fungal culture, of which 4 (8%) were positive, with growth of either Candida albicans or
Aspergillus fumigatus. All BAL samples sent for mycobacterial culture (n = 47) were
negative. Each patient with positive bacterial or fungal cultures had no evidence of focal
parenchymal consolidation on chest x-ray. Two patients were treated with a course of
antibiotics after bacteria grew from their BAL cultures. Viruses were identified in 6 (14%) of
the 42 BAL samples sent for virology, and rhinovirus was the most common virus identified
in 5 samples (Table 2). Baseline casting frequency was similar between patients with
positive and negative BAL infectious studies, where positive BAL infectious studies were
defined as either a positive viral PCR or positive bacterial or fungal culture. Repeat analysis
excluding all patients with positive fungal cultures was also not significant.
Cast Analysis Results
The gross morphology of a cast removed during bronchoscopy is shown in Figure 2, Panel
A. Nineteen patients produced one or more casts within one month of procedure, which
were analyzed separately as 23 cast specimens (Table 3). Twenty-one casts were removed
during the bronchoscopy concurrent with intervention, one was spontaneously expectorated,
and one was removed from a patient’s gastrostomy tube.
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All 23 cast specimens contained scattered lymphocytes. Nineteen (83%) casts were
composed of dense proteinaceous material (Figure 2, Panel B). Looser basophilic mucin
that contained muciphages was located at the edges or occasionally layered with the
proteinaceous material. Fourteen of the 19 proteinaceous casts contained neutrophils and/or
eosinophils. The neutrophils and eosinophils were usually within the adjacent mucin and
only focally embedded in the proteinaceous material. Only 2 casts (9%) contained both
prominent proteinaceous and mucinous components (Figure 2, Panel C), and 2 casts (9%)
were predominantly mucinous (Figure 2, Panel D). Only 4 (17%) of the 23 specimens
analyzed lacked any neutrophils and eosinophils. In patients with multiple specimens there
was variation in proteinaceous and mucous content, presence or absence of neutrophils, and
presence or absence of eosinophils. The presence of a positive bacterial culture was
identified in 6 of the proteinaceous specimens.
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We sought to determine whether BAL neutrophil count and baseline casting frequency were
different in patients with casts containing neutrophils and/or eosinophils versus casts without
these cellular components. The median BAL neutrophil cell count associated with
proteinaceous casts containing neutrophils and/or eosinophils was greater than the median
neutrophil cell count associated with proteinaceous casts without neutrophils and
eosinophils (43 vs. 17, p = 0.030). Proteinaceous casts containing neutrophils and/or
eosinophils were not associated with a statistically significant difference in median BAL
lymphocyte count, median BAL eosinophil count, and baseline casting frequency when
compared to proteinaceous casts without neutrophils and eosinophils
Pediatr Pulmonol. Author manuscript; available in PMC 2019 November 01.
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Sixty patients were alive at the time of follow-up and contacted to complete the standardized
post-intervention questionnaire. Forty-eight patients responded, yielding a response rate of
80%. The median time from intervention to follow-up was 20 months (IQR 15-32 months).
The median daily oxygen saturation reported by families at the time of follow-up was 93%
(IQR 90-96%). Thirty (63%) respondents reported that their child’s oxygen saturations were
higher after the lymphatic intervention. One respondent reported a decrease in oxygen
saturation post-intervention, while the remainder reported no change. Four patients whose
families’ responded to the questionnaire had undergone heart transplantation during the
follow-up period. All transplanted patients continued to cast intermittently post-intervention,
had cessation of casting immediately post-transplantation, and were off all respiratory
medications at time of follow-up. These 4 patients were considered treatment failures and
were excluded a priori from our pre- and post-intervention analyses of intermediate-term
outcomes so that their positive outcomes would not be falsely attributed to lymphatic
intervention success.
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Pre-intervention and post-intervention respiratory medications and support for the remaining
44 patients transplanted were analyzed. There was a statistically significant reduction in the
need for inhaled tPA and respiratory support (Table 4). A number of patients were also being
treated with albuterol, inhaled steroids, hypertonic saline, dornase alfa, montelukast,
azithromycin, and systemic steroids. While none of these specific medications, except for
inhaled tPA, have been shown to be reliably effective in the treatment of PB, there were
statistically significant reductions in all medications except montelukast and systemic
steroids post-intervention. In addition to these changes in respiratory therapies, there was a
significant decrease in casting frequency at intermediate-term follow-up (p < 0.0001). In
those patients with continued casting after initial intervention, 79% reported that casts
expectorated post-intervention appeared smaller than those expectorated pre-intervention.

Discussion
In this study, we characterize BALs and cast morphology in patients with surgically repaired
CHD and PB at time of lymphatic intervention. We sought to assess bronchoscopy safety
and intervention efficacy by quantifying respiratory outcomes post-intervention. This study
provides the largest cohort of patients with PB to date and provides a homogenous cohort
due to common underlying congenital heart disease.
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In our cohort we were able to demonstrate successful removal of casts with flexible
bronchoscopy in a controlled setting without respiratory complications or airway
obstruction. While not used in this current cohort, further advancement in our technique of
cast removal has included the use of CryoProbe, which has enhanced our ability to remove
casts.
Our study is the first to describe the BAL characteristics of patients with PB. We
hypothesized that casts containing neutrophils and/or eosinophils would be associated with
neutrophilic BALs. Our study demonstrates higher counts of neutrophils and decreased
counts of macrophages in patients with PB at the time of BAL collection in comparison to
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healthy children and adults22,23. Of note, while 42% of patients had elevated lymphocytes on
BAL, the median BAL lymphocyte count was comparable to that of healthy children and
adults. These findings are unexpected given that bronchial casts are thought to derive from
the lymphatic system, and we would expect BAL lymphocyte count to be elevated7,16. It is
possible however, that those patients with normal BAL lymphocyte counts did not have
current or recent casting in the area of lung from which the BAL was obtained. This would
be consistent with findings of PLPS with significant anatomical variations of the central
lymphatic system.
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In addition, 14% of BALs tested for virology were positive for viruses and 19% of BALs
tested were positive for either bacteria or fungus. While the patients with positive bacterial
cultures had no evidence of focal parenchymal consolidation on chest x-ray and were not
being treated with antimicrobials, 5 of the 6 patients had elevated neutrophils on BAL,
consistent with a diagnosis of bacterial bronchitis24. The positive BAL fungal cultures more
likely represent colonization or sample contamination in these patients in the absence of
other clinical symptoms and treatment. The high percentage of positive BAL infectious
studies supports case reports that lower respiratory infection, particularly influenza, may
facilitate or exacerbate cast formation25. However, we cannot exclude the possibility that
cast obstruction may facilitate infectious colonization and subsequent infection in the
airways.
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The morphology of bronchial casts remains a subject of continued debate3,5,10. We observed
that all casts contained some scattered lymphocytes, but that proteinaceous and neutrophilic
casts represented the most common cast morphology. Patients with neutrophilic casts had
higher BAL neutrophil counts. Our findings that patients with congenital heart disease
produce proteinaceous, cellular casts with surrounding mucin are consistent with the
findings of Heath et al10. While chylous fluid is composed predominantly of fibrin and
lymphocytes, our finding that bronchial casts also contain neutrophils suggests that acute
inflammation and possibly infection plays a role in cast formation.
In our analysis of baseline casting frequencies, we found similar results in patients with
positive and negative BAL infectious studies and in patients with inflammatory and noninflammatory casts. These findings suggest that underlying cast morphology and infection
are not the main determinants of casting frequency.
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These observations provide important insight into the pathogenesis of PB in patients with
surgically repaired CHD. Based on previous studies, elevated central venous pressures and
impaired cardiac output are thought to facilitate increased lymph formation and abnormal
lymphatic flow9. Abnormal pulmonary lymphatic flow, known as PLPS, causes alveolar
injury and exudation of fluid into the tracheobronchial tree, ultimately leading to cast
formation. The predominance of neutrophilic, proteinaceous casts and the BAL evidence of
pulmonary infectious material may indicate that inflammation plays a role in cast
development. The finding that baseline casting frequency is independent of pulmonary
infectious material and cast morphology is consistent with the hypothesis that casting
frequency is primarily driven by the extent of lymphatic and cardiac hemodynamic
abnormalities.
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At a median follow-up time of 20 months, PCL was associated with a significant decrease in
respiratory medications and support, in addition to casting frequency. While a number of
treatments aimed at improving both cardiac hemodynamics and cast expectoration have
demonstrated utility, current PB treatments primarily target symptom management and do
not afford complete casting resolution10–13. Not only does PCL result in improved casting
frequency, it also results in a significant reduction in the number of respiratory therapies
required to manage PB symptoms.
Limitations
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Our study has several important limitations. First, this is a retrospective single-center study
and therefore may not represent the whole population of patients with surgically repaired
CHD and PB. Our institution is currently the only one performing PCL, and therefore, there
may be a selection bias in the patients represented in this cohort. Cast composition may have
been altered in patients who had been treated with fibrinolytic and anti-infective
medications. Some patients were unable to be contacted by phone for follow up, which may
reflect response bias. If non-responders had worse outcomes, then our findings would
overestimate intervention efficacy. While our study demonstrates reduced need in CHD
patients for respiratory therapies post-intervention, it may not be appropriate to extrapolate
these outcomes to patients with PB secondary to a non-cardiac etiology.

Conclusion
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Patients with surgically repaired CHD and PB predominantly produce lymphocytic
proteinaceous casts and have a high percentage of positive BAL infectious studies,
suggesting that short-term fibrinolytics and anti-infective medications may be effective
treatment options in select patients. When performed by experienced bronchoscopists,
flexible bronchoscopy concurrent with PCL is a safe option to assess for cast burden and
airway damage. PCL at our institution provides intermediate-term reductions in casting
frequency and respiratory medications and support, thereby demonstrating that it is a
reliably effective therapy for PB. Continued longitudinal study of these patients is required
to assess the complications of lymphatic intervention and determine whether it offers a
permanent solution to plastic bronchitis.
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Figure 1:
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Bronchoalveolar lavage cell counts (n = 54). Box and whisker plot diagram illustrating 5
number summary. Bronchoalveolar lavage cellular patterns in normal/healthy children and
adults, per 100 cells: alveolar macrophages (>85), neutrophils (<3), lymphocytes (10-15),
and eosinophils (<1).
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Figure 2:

(A) Gross image of cast removed via bronchoscopy, (B) Proteinaceous cast section, (C)
Mixed proteinaceous and mucinous cast section, (D) Mucinous cast section. All histology
images hematoxylin and eosin stained, 40×.
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Demographics and Baseline Characteristics
Patient Characteristic

Value

Male sex

41 (65%)

Age at intervention, years

9 (5-12)

Time from most recent cardiac surgery to PB onset, months

20 (4-47)

Physiology at time of intervention (based on surgical repair)
Fontan physiology

54 (87%)

†

2 (3%)

Glenn physiology

‡

2-Ventricle physiology

Time from PB onset to intervention, months

6 (10%)
9 (4-43)

Cast frequency

Author Manuscript

Daily

19 (31%)

Every few days

1 (2%)

Weekly

16 (26%)

Every few weeks

13 (21%)

Monthly

7 (11%)

Every few months

6 (10%)

Casting in 1 month prior to intervention

56 (90%)

Values expressed are expressed either as median (IQR) or number (percentage).
PB = plastic bronchitis

†

Glenn physiology includes patients status-post Fontan takedown prior to lymphatic intervention.

‡

2-Ventricle physiology includes patients with congenital heart disease status-post orthotopic heart transplantation prior to lymphatic intervention.
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Bronchoalveolar Lavage Infectious Study Characteristics
Study

Number positive (%)

Bacterial culture (n = 54)
Any positive bacterial culture

6 (11%)

Moraxella catarrhalis

2

Pseudomonas aeruginosa

2

Staph aureus

1

Staph aureus + Haemophilus influenzae

1

Fungal culture (n = 50)
Any positive fungal culture

4 (8%)

Candida albicans

3

Aspergillus fumigatus

1

Author Manuscript

Mycobacterial culture (n = 47)
Any positive mycobacterial culture

0 (0%)

Virology (n = 42)
Any positive virology*

6 (14%)

Adenovirus

2

Human Metapneumovirus

1

Parainfluenza 3

1

Rhinovirus

5

Respiratory Syncytial Virus

1

N represents number tested.

*

Viral subtypes not mutually exclusive.
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Cast Histology

Cast Histology

n (%)

BAL Neutrophil
Count, per 100
cells

BAL Lymphocyte
Count, per 100
cells

BAL Eosinophil
Count, per 100
cells

12 (63%)

43 (20-61)

13 (12-21)

0 (0-0)

Lymphocytic Proteinaceous (n=19)
With neutrophils

Embedded in proteinaceous material

1

Peripheral in mucin

7

43 (11-57)

17 (12-27)

0 (0-0)

Both

4

42 (22-85)

12 (5-13)

0 (0-0)

With neutrophils (peripheral) and eosinophils

2 (11%)

44

21

11

Without eosinophils and neutrophils

0 (0-5)
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5 (26%)

21 (9-22)

12 (9-34)

Proteinaceous with positive cultures*

6 (32%)

22 (21-69)

12 (10-19)

0 (0-0)

Proteinaceous with negative cultures

13 (69%)

21 (7-56)

20 (10-34)

0 (0-10)

With neutrophils (peripheral)

1

54

5

0

With neutrophils and eosinophils (both)

1

67

7

12

2

30

25

0

Lymphocytic mixed mucinous and proteinaceous (n = 2)

Lymphocytic mucinous with embedded neutrophils (n = 2)

Values are reported as number with percentage of total and median with IQR.

*

Positive cultures represent either positive BAL virology or BAL bacterial or fungal culture.
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Use of Inhaled tPA and Respiratory Support Pre- and Post-Intervention
Treatment

Pre-intervention (n = 44)

Inhaled tPA
Respiratory Support, any
Nasal cannula

Post-intervention (n = 44)

P-value

21 (48%)

1 (2%)

<0.0001

18 (41%)

7 (16%)

0.0042

14 (32%)

4 (9%)

Intermittent CPAP/BLPAP

3 (7%)

3 (7%)

Continuous CPAP/BLPAP

1 (2%)

0 (0%)

Values are reported as n (%). P-values calculated using McNemar’s test.
tPA = tissue plasminogen activator. CPAP/BLPAP = Continuous positive airway pressure/Bi-level positive airway pressure.
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